# US 2018/0021369 A1 · Treatment of bone marrow edema (oedema) with polysulfated polysaccharides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021369 A1
- Document ID: US20180021369A1
- Status: Published application
- Kind: A1
- Application number: 15/720,884
- Filed: 2017-09-29
- Published: 2018-01-25
- Earliest claimed: 2011-02-02
- Assignees: Paradigm Health Sciences Pty Ltd
- Applicants: Paradigm Health Sciences Pty Ltd
- Inventors: Peter Ghosh
- Web page: https://patentgrep.com/patent/US20180021369A1

## CPC

- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for the treatment of bone marrow edema in a mammal comprising administering an effective amount of a polysulfated polysaccharide including salts thereof, to a mammal in need of such treatment.

## Claims

### Claim 1

A method for the treatment of bone marrow edema in a mammal, comprising:
subjecting the mammal to a magnetic resonance imaging process,
assessing one or more images generated from the magnetic resonance imaging process so as to detect the presence of a bone marrow edema,
administering from about 1 mg/kg to about 2 mg/kg per dose of a polysulfated polysaccharide selected from the group consisting of pentosan polysulfate, a sodium salt of pentosan polysulfate (NaPPS), a magnesium salt of pentosan polysulfate (MgPPS), and a calcium salt of pentosan polysulfate (CaPPS) to the mammal if the bone marrow edema is detected in the mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mammal is a human subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein the administering is by a route selected from the group consisting of intra-articular, peri-articular, subcutaneous, and intramuscular.

### Claim 4 (depends on 3)

The method of claim 3, wherein the administering is intra-articular.

### Claim 5 (depends on 3)

The method of claim 3, wherein the administering is peri-articular.

### Claim 6 (depends on 3)

The method of claim 3, wherein the administering is intra-muscular.

### Claim 7 (depends on 3)

The method of claim 3, wherein the administering is subcutaneous.

### Claim 8 (depends on 3)

The method of claim 3, wherein the administering is continued on a daily basis until the human subject has received a total dose of about 200-2000 mg of the polysulfated polysaccharide.

### Claim 9 (depends on 8)

The method of claim 8, wherein the polysulfated polysaccharide is sodium pentosan polysulfate.
